Chimerix Inc

Chimerix — Investor Presentation (November 2017)

50 slides from Chimerix's investor presentation, Nov 14, 2017

  1. Slide 1: Investor Update November 2017

    INVESTOR UPDATE NOVEMBER 2017

  2. Slide 2: Forward-Looking Statements

    2 Forward - Looking Statements These slides and the accompanying oral presentation contain forward - looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility tha

  3. Slide 3: Oral BCV

    K ORAL BCV

  4. Slide 4: CMRX: Developing Solutions for Immunocompromised Patients

    4 CMRX: Developing Solutions for Immunocompromised Patients ▪ Mature management team with significant antiviral drug development and first - in - indication commercial experience ▪ Lead compound brincidofovir has broad spectrum antiviral activity – In late - stage development for treatment of smallp

  5. Slide 5: BCV: The Only Broad Spectrum Antiviral in Development

    5 BCV: The Only Broad Spectrum Antiviral in Development Vi r a l F am ily Virus BCV Ci do f o vir M a ri b a vir Let e rm o vir G a n c i c l o vir* F o s c a r ne t A c y c l o vir H e rp e s C y t om e g a lovirus 0 . 00 1 0 . 4 0 . 31 0 . 005 3 . 8 5 0 - 800 > 2 00 E p s t e i n - B a rr Virus 0

  6. Slide 6: Brincidofovir Concentrates the Active Antiviral in the Cell

    6 Brincidofovir Concentrates the Active Antiviral in the Cell Active Antiviral (CDV - PP) Inactive Drug KEY: Cidofovir Brincidofovir

  7. Slide 7: SUPPRESS for CMV Prevention: Efficacy Confounded by GI Toxicity

    7 SUPPRESS for CMV Prevention in High - Risk Allo - HCT: Brincidofovir Efficacy Was Confounded by GI Toxicity Subjects on brincidofovir: ▪ Demonstrated a statistically - significant reduction in CMV reactivation while on therapy ▪ Had drug - related diarrhea erroneously diagnosed as gut GVHD ▪ Gut b

  8. Slide 8: Oral Brincidofovir for Treatment of AdV: Development and Approval Timelines

    8 Oral Brincidofovir for Treatment of AdV: Development and Approval Timelines ▪ AdAPT was designed with EU regulators to provide a small comparative study of oral BCV for short - course treatment of AdV ▪ AdAPT should provide data sufficient for a conditional or full approval in Europe ▪ Data from A

  9. Slide 9: Short-course Oral BCV for Adenovirus: Maximizing Probability of Success for AdAPT

    9 Short - course Oral BCV for Adenovirus: Maximizing the Probability of Success for AdAPT ▪ Rapid identification and treatment of AdV viremia is key: – Screening must be conducted at least weekly at centers participating in the trial – Intervention with oral brinci as quickly as possible after confi

  10. Slide 10: Adenovirus in Peripheral Blood Associated With High Transplant-Related Mortality

    0 0.2 0.4 0.6 0.8 1 0 30 60 90 120 150 180 210 240 270 300 330 360 pSU Days after first AdV positivity in PB 67% ( + 5%) 64% ( + 10%) 18% ( + 9%) (P< 0.001) AdV viremia AdV negative AdV positive at sites other than peripheral blood (PB) Post - transplant Survival 10 Adenovirus Detected in Peripheral

  11. Slide 11: AdVise: BCV Begun at Lower Viral Loads Clears AdV Within 4 Weeks

    11 AdVise: BCV Begun When AdV Viral Loads Are Lower (<6 log 10 c/mL) Results in Undetectable AdV Within 4 Weeks Time to AdV plasma clearance (pediatrics) Short - course Oral BCV should result in clearance of AdV in majority of patients ▪ Pediatric pts with lower AdV viral loads at baseline (<10,000

  12. Slide 12: Phase 2 in Asymptomatic AdV: Oral BCV BIW Cleared Plasma in 1 Week

    Phase 2 in Asymptomatic AdV: Oral BCV BIW Cleared Plasma in 1 Week if AdV >1000 c/mL ▪ Study 202: allo - HCT recipients with asymptomatic AdV viremia were randomized to oral BCV twice weekly, oral BCV once weekly, or placebo (n=48) ▪ Learnings: – Low risk patients including recipients of T - cell re

  13. Slide 13: Early Treatment of AdV Correlated with Higher Survival in AdVise

    13 Early Treatment of AdV Correlated with Higher Survival in AdVise ▪ Because AdVise began as an outgrowth from our expanded access program, patients enrolled at the beginning of the trial had high AdV viral loads, extensive prior cidofovir use, and the longest period from diagnosis to first dose of

  14. Slide 14: AdV Reactivation from the Gut Drives Disease After HCT

    14 AdV Reactivation from the Gut Drives Disease After HCT Detection of AdV in stool and viremia Lion et al. Leukemia 2010, 24(4):706 - 14 37% have AdV in stool lower AdV load ≤ 1x10 6 /g no/slow replication kinetics high AdV load 5x10 6 - 10 11 /g rapid replication kinetics No viremia >70% viremia (

  15. Slide 15: BCV Clears AdV from Plasma With or Without Immune Function

    15 BCV Clears AdV from Plasma With or Without Immune Function, While Cidofovir Requires Immune Assistance Patients on oral BCV were able to clear AdV viremia even with lower lymphocyte counts ▪ Immune reconstitution: absolute lymphocyte count >300 cells/ uL ▪ Allo - HCT pts that receive T - cell dep

  16. Slide 16: AdAPT: Adenovirus after Allogeneic Pediatric Transplantation

    Follow up Period Potential Treatment Period Potential Treatment Period AdAPT: Ad enovirus after A llogeneic P ediatric T ransplantation ▪ Open label, comparative study of o ral BCV vs. standard of care (SoC) – P ediatric T - cell depleted allo - HCT recipients in 1 st 100 d ays of HCT with AdV ≥ 100

  17. Slide 17: Adenovirus Area Under the Curve (AUC)

    17 Adenovirus Area Under the Curve (AUC) ▪ Measuring Antiviral Activity ▪ Antivirals for acute infections have two major impacts: – Decrease peak viral load – Shorten time to viral clearance ▪ Both parameters are captured when measuring viral area under curve (AUC) ▪ Impact is highest when applied e

  18. Slide 18: Quantifying Viral Burden: Time-Averaged Area Under the Curve

    18 Quantifying Viral Burden: Time - Averaged Area Under the Curve ▪ Advantages of AAUC endpoint ▪ Precedent: use of AUC was established with HIV antiretrovirals ▪ Comprehensive: – Sum of viremia over time at risk as opposed to clearance at specified timepoint – Allows capture of viral recurrences –

  19. Slide 19: Quantifying Viral Burden: Time-Averaged Area Under the Curve

    19 Quantifying Viral Burden: Time - Averaged Area Under the Curve AdV DNA copies/mL AAUC = Average AdV viral load over 16 weeks AdV DNA baseline + AdV DNA Wk1 + AdV DNA Wk2 + … AdV DNA Wk16 16 Weeks

  20. Slide 20: Rapid Antiviral Effect of Oral BCV vs SoC

    Average Viral Load = 2.03 log 10 copies/mL Average Viral Load = 3.89 log 10 copies/mL Average Viral Load = 4.40 log 10 copies/mL Average Viral Load = 2.39 log 10 copies/mL 20 Rapid Antiviral Effect of Oral BCV vs SoC Oral BCV (AdVise) Standard of Care (SoC) (AdVance) 3 yo, ex vivo TCD+ATG, 41d post

  21. Slide 21: UK Consortium Data: Oral BCV Expected to Deliver Lower Average AdV Viral Loads

    21 Based on Independent UK Consortium Data, Oral BCV Expected to Deliver Lower Average AdV Viral Loads in AdAPT ▪ UK consortium: Oral BCV decreased peak viral load and shortened time to viral clearance when compared to SoC1 ▪ AdAPT has >90% power to demonstrate superiority of BCV vs. SoC if the true

  22. Slide 22: Viral Load Matters: Lower AdV Burden Correlates with Lower Mortality

    3.2 log 4.4 log Dead Alive 22 Viral Load Matters: Lower AdV Burden Correlates with Lower Week 16 Mortality ▪ The AdVance study captured practice patterns and outcomes in EU allo - HCT recipients with AdV infection treated with current SoC ▪ AdV AAUC in pediatric HCT recipients in UK, France, and Spa

  23. Slide 23: Summary: AdAPT Design is Finalized

    23 Summary: AdAPT Design is Finalized ▪ Adenovirus viral burden is an optimized endpoint for AdAPT ▪ We will use average viral load over 16 weeks as our measurement – EU CHMP and US FDA have agreed to primary endpoint for AdAPT – Average viral load has been used in prior pivotal studies – Viral burd

  24. Slide 24: What is Different About AdAPT vs AdVise and SUPPRESS?

    24 What is different about AdAPT vs AdVise and SUPPRESS? AdAPT AdVise SUPPRESS Controlled ✔ ✔ Open - label vs blinded Open - label Open - label Blinded Treatment initiation Pre - emptive Treatment Prevention Treatment initiated during 1 st 100 days post - transplant ✔ ✔ Treatment initiated within 3

  25. Slide 25: IV BCV

    IV BCV

  26. Slide 26: IV Brincidofovir for Multi-Viral Prevention: Development and Approval Timelines

    26 IV Brincidofovir for M ulti - V iral P revention in HCT Recipients: Development and Approval Timelines ▪ MVP may provide the opportunity to demonstrate the importance of preventing multiple DNA viral infections in a placebo - controlled pivotal study in a high - risk population 201: Phase 2 dose

  27. Slide 27: IV BCV May Avoid GI Side Effects, Allow Longer-term Dosing

    IV BCV May Avoid GI Side Effects, Allow Longer - term Dosing ▪ IV BCV 10 mg provided equivalent plasma drug levels as oral BCV 100 mg which provided antiviral activity in prior studies ▪ IV BCV 10 mg and 25 mg were very well tolerated – No GI AEs reported – No other significant AEs or lab changes ▪

  28. Slide 28: New IV Formulation of BCV May Result in Improved Tolerability

    28 New IV Formulation of BCV May Result in Improved Tolerability In rats, IV BCV: ▪ delivered more uniform drug exposure levels to the small intestine, liver and kidney ▪ resulted in higher central nervous system concentrations, which may support testing of this formulation in viral infections in th

  29. Slide 29: IV BCV May Allow Treatment & Prevention of Multiple DNA Viruses

    Increased Risk of Reversible GI Adverse Events and ALT Elevations 29 IV BCV May Allow Treatment & Prevention of Multiple DNA Viruses Treatment of CMV Treatment of AdV Short - term dosing achieved with oral BCV Multi - Viral Prevention Longer dosing required – to be pursued with IV BCV BCV AUCs ( ng.

  30. Slide 30: Adult and Pediatric HCT Recipients Face Risks Beyond CMV

    Adult and Pediatric HCT Recipients Face Risks Beyond CMV ▪ Of the HCT recipients who reactivated CMV, >75% had at least one other DNA virus identified and were at increased risk of mortality ▪ 1 in 3 HCT recipients had ≥3 DNA viral infections detected ▪ Pediatric Allo - HCT recipients commonly react

  31. Slide 31: Following Transplant, Viruses Reactivate Early and Persist

    31 Following Transplant, Viruses Reactivate Early and Persist Hill et al, BMT Tandem meeting 2016 0 5 10 15 20 25 30 35 40 45 2 4 6 8 10 12 14 CMV BKV HHV-6 AdV EBV Proportion of patients with each virus Week after Transplant Cumulative Incidence First 100 Days Post - HCT: CMV 64% BKV 54% HHV - 6 47

  32. Slide 32: More DNA Viruses Reactivating = Higher Mortality

    Log - rank 0 - 3 vs. ≥4, p=0.019 Log - rank 0 - 1 vs. 2 vs >2, p=0.026 Number of DNA viruses at any time Number of DNA viruses at the same time 32 More DNA Viruses Reactivating = Higher Mortality Hill et al, Blood 2017 Cumulative viral load AUC was associated with mortality, after adjusting for immu

  33. Slide 33: IV Brinci May Prevent Life-threatening DNA Viral Infections: Multi-Viral Prevention

    IV Brinci May Prevent Life - threatening DNA Viral Infections: M ulti - V iral P revention ▪ The lower risk of GI side - effects with IV BCV may allow longer duration of dosing needed for patients throughout the period of highest risk (first 100 days post - transplant) ▪ All patients undergoing allo

  34. Slide 34: Multi-Viral Prevention Peds: IV BCV for Prevention of AdV and Other DNA Viruses

    Follow up Period 34 Multi - Viral Prevention Peds : IV BCV for Prevention of AdV and other DNA Viruses After HCT ▪ Randomized, double - blind trial of IV BCV vs. placebo – Population: pediatric allo - HCT with >10 6 log 10 c/g AdV DNA in stool, <100 days from HCT ▪ Primary endpoint: proportion with

  35. Slide 35: Potential for IV BCV in Other DNA Virus Infections: BK Virus

    35 Potential for IV BCV in Other DNA Virus Infections: BK Virus ▪ Both SOT and HCT recipients are at risk for BKV infections – HCT: hemorrhagic cystitis requiring hospitalization for pain control – Kidney transplant recipients: BKV associated nephropathy with risk of graft loss and a return to dialy

  36. Slide 36: BCV Market Potential: Global Opportunities in Transplant and Malignancies

    36 BCV Market Potential: Global Opportunities in Transplant and Malignancies US HCT: 2014 figures from CIBMTR. Auto - HCT are increased by 20% to account for under - reporting to CIBMTR. US SOT: 2015 figures from Organ Procurement and Transplantation Network (OPTN). EU HCT: JR Passweg , et al., HSCT

  37. Slide 37: Opportunities in the Growing Transplant Market

    Opportunities in the Growing Transplant Market ▪ US HCT: 2014 figures from CIBMTR. Auto transplants are increased by 20% to account for under - reporting to CIBMTR. ▪ US SOT: 2015 figures from Organ Procurement and Transplantation Network (OPTN). ▪ EU HCT: JR Passweg , et al., HSCT in Europe 2014, n

  38. Slide 38: AdVance: Incidence and Outcomes of AdV Infections in Allo-HCT Recipients

    AdVance: Incidence and Outcomes Associated with the Management of AdV Infections in Allo - HCT Recipients ▪ Three components of the AdVance study: 1. What are the European practice patterns associated with AdV infection in allo - HCT population (i.e., diagnosis, screening, treatment)? 2. What is the

  39. Slide 39: BCV: Opportunities For Treatment of AdV Beyond Transplant

    39 BCV: Opportunities For Treatment of AdV Beyond Transplant U.S. AdV - Related Hospital Discharges: 2009 - 2014 Actual, Trended From 2015 ▪ In addition to stem cell and organ transplant recipients, other at - risk populations include newborns with severe combined immunodeficiency (SCID), individual

  40. Slide 40: Most U.S. AdV-Related Hospitalizations Are Not in Transplant or Immunocompromised Patients

    40 Most U.S. AdV - Related Hospitalizations are NOT in Transplant Recipients or Immunocompromised Patients Projected AdV - related hospitalizations AdV + transplant procedure and/or complication AdV + immunocompromised * Diagnosis code AdV + other diagnosis code (NOT transplant or immunocompromised)

  41. Slide 41: Building Full Potential Value for Oral and IV BCV – Land

    41 Building Full Potential Value for Oral and IV BCV – “Land” Utilize Get - to - Market Regulatory Strategy in Adenovirus Population Pediatric & Adult Allo - HCT Recipients Treatment & Prevention Pediatric & Adult Auto HCT and SOT Recipients Treatment Immunocompromised AdV Patients Treatment “ Other

  42. Slide 42: Building Full Potential Value for Oral and IV BCV – Expand

    Multiviral Protection in Ped and Adult Allo - HCT BKV Treatment in Allo - HCT and SOT Other Uses of IV Brinci in DNA Viral Infections 42 Building Full Potential Value for Oral and IV BCV – “Expand” Pediatric & Adult Allo - HCT Recipients Treatment & Prevention Pediatric & Adult Auto HCT and SOT Reci

  43. Slide 43: Land and Expand Strategy

    43 “Land and Expand” Strategy ▪ Land : Establish the beach - head in pediatric Allo - HCT recipients with AdV in AdAPT – Expand understanding of AdV infections in non - transplant patients ▪ Expand: Demonstrate Multi - Viral Prevention with IV BCV in pediatric patients in MVP - Peds – Educate HCPs a

  44. Slide 44: Oral BCV for Smallpox

    44 Oral BCV for Smallpox ▪ Efficacy to be demonstrated via two animal model studies under FDA’s Animal Rule – Pivotal Rabbitpox Efficacy Study demonstrated 100% survival in animals treated immediately with BCV at the time of confirmed infection – Pivotal Mouse Pox (ectromelia) study to be conducted

  45. Slide 45: Smallpox Threat

    Smallpox Threat ▪ Population is largely unvaccinated ▪ Undeclared stocks of variola virus – Official stocks are at CDC in Atlanta and Vector Labs in Novosibirsk, Russia – High likelihood of undeclared stocks – 2014 incident - live variola virus stocks found at NIH Bethesda campus ▪ “Old” virus: Thaw

  46. Slide 46: Norovirus: New Clinical Candidate CMX521 On Track

    46 Norovirus: New Clinical Candidate CMX521 On Track ▪ Significant Unmet Need/Opportunity – Acute prophylaxis: ~ 20 million cases/year in the US; most reported outbreaks (>60%) are in health care facilities 1 – Treatment: chronic norovirus infection is associated with chronic, severe diarrhea & graf

  47. Slide 47: Norovirus Outbreaks Occur Over a Number of Days, Allowing for Intervention

    47 Norovirus Outbreaks Occur Over a Number of Days, Allowing for Intervention 66% 94% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Percent Treated Days from onset of outbreak Brazil Kansas One week into an outbreak, 2/3 to >90% of indi

  48. Slide 48: Chimerix Continues to Build a Pipeline of Solutions

    48 Chimerix Continues to Build A Pipeline of Solutions for Patients at Risk of Serious Viral Infections 2017 2018 2021 MVP DATA 2019 2020 IV BCV for Multi - Viral Prevention 2022 AdAPT DATA Oral BCV for AdV CMX521 SAD/MAD CMX521 POC CMX521 Treatment of Norovirus CMX521 Prevention of Norovirus DATA C

  49. Slide 49: Clinical Pipeline

    49 Clinical Pipeline Program Indication Pre - clinical Phase 1 Phase 2 Phase 3 Status Anticipated Approval Short - course Oral BCV AdV Treatment Plan t o start AdAPT 4Q17 2020 Smallpox Animal rule model in process 2020 IV BCV Multi - viral Prevention Treatment of CMV/BK MAD Data expected year end 20

  50. Slide 50: CMRX: Progressing Solutions for Immunocompromised Patients

    50 CMRX: Progressing Solutions for Immunocompromised Patients ▪ Oral brincidofovir: AdAPT trial in US and EU for pediatric transplant recipients with adenovirus infection by year end 2017 ▪ IV brincidofovir: progressing towards a pivotal study planned for initiation in 2018 for prevention of multipl

Chimerix — Investor Presentation (November 2017) on 6ix